Minichromosome maintenance (MCM) and AgNOR proteins expression in desmoid tumours: a tissue microarray analysis. by Ferenc, Tomasz et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 581 (581-588) 
Doi: 10.2478/v10042-010-0087-y
Introduction 
Desmoid-type fibromatoses are clonal fibroblastic pro-
liferations that arise in the deep soft tissues and are char-
acterized by infiltrative growth and a tendency toward
local recurrence but by inability to metastasize [1]. Des-
moids are composed of fibrocytes, fibroblasts and
myofibroblasts surrounded and separated by abundant
collagen or foci with mucoid stroma [1,2]. Desmoid
tumours are characterized by the proliferation of reper-
ative type myofibroblasts [3].   
Tumour proliferation represents the convergence of
many cellular factors, including cell cycle time,
growth fraction, population doubling time, and cell
loss. These factors depend upon the cell cycle phases
[4-6]. The proliferative capacity of tumour cells is a
fundamental feature of tumour growth [7]. Information
about the cellular proliferation rate on paraffin sections
of the same tissue can be obtained by immunohisto-
chemical detection of the Ki-67 protein [5,7-9],
minichromosome maintenence (MCM) proteins [10-
15], and the histochemical assessment of silver-stained
AgNOR proteins [16,17].                                           
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Abstract: In the present study, nuclear proliferative proteins: MCM2, MCM5, MCM7, Ki-67 and AgNORs expression was
assessed in paraffin sections from sporadic desmoid tumours using a tissue microarray (TMA)-based immuno- and histo-
chemistry, respectively. Nuclear expression of MCM7, where the percentage of positive cells was 0.87% (±1.64) (range 
0-5%), was found in 4/20 (20.0%) cases. In 32/32 (100%) of the examined desmoid cases no expression of nuclear proteins
MCM2 and MCM5 was detected. Nuclear expression of Ki-67 was observed in 4/21 (19%) cases. Paraffin sections from 
30 cases of desmoid tumours were silver-stained to visualize AgNORs. The following AgNOR parameters were calculated:
mean AgNOR number per nucleus (N), mean AgNOR area per nucleus, mean AgNOR dot area per nucleus (A), and mean
AgNOR content (C = N/A). In the investigated group the mean values of AgNOR parameters were the following number:
4.34 (±0.11); area: 0.74 μm2 (±0.19); dot area: 0.18 m2 (±0.01), and AgNOR content: 23.73 (±1.85). The mean AgNOR num-
ber per nucleus and mean AgNOR content in desmoid tumours were statistically significantly higher as compared to the con-
trols (tonsil tissue) (p<0.001). This study observed low level of MCM7 and Ki-67 and lack of MCM2, MCM5 proteins
expression which may explain commonly known low mitotic activity of desmoid tumour cells. The morphology of dots
related to AgNORs (number, area) and their morphometric parameters point to elevated transcriptional activity of desmoid
cells.
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MCM proteins are essential for the initiation and
progression of DNA replication in eukaryotes. Among
them the best known are MCM2-7, a family of six
highly conserved proteins which are key components
of the prereplicative complex (pre-RC) that initiates
DNA synthesis in all eucaryotes [18-20]. The
minichromosome maintenace genes (MCM2-7) are
transcribed at M/G1 phase boundary [21]. The nuclear
localization of the MCM2-7 complex is regulated by
the cyclin-dependent kinases (CDKs) [18,20-22].
MCM2-7 are imported into the nucleus when CDK
activity is low in early G1 and exported from the
nucleus during S phase when CDK activity is high
[21]. In mammalian cells in G1 phase majority of
MCM proteins are associated with chromatin. In S
phase nearly the whole amount of MCM proteins dis-
sociate from the chromatin and only small fraction of
them remains bound to regions of unreplicated DNA
[18,21]. During G2/M phase MCM proteins are absent
on chromatin and are detectable predominantly in
cytoplasm where they later undergo enzymatic degra-
dation [18,21]. As cells exit mitosis these newly syn-
thesized MCM proteins accumulate in the nucleus
(early G1 phase) and assemble into pre-RC [21].
Human MCM2-MCM7 have recently been considered
as new proliferating antigens [10,13,14,23,24].
Nucleolar organizer regions (NORs) are ribosomal
DNA (rDNA) sequences on the short arms of human
acrocentric (D and G group) chromosomes, which
encode ribosomal RNA (rRNA) [25]. In cycling cells,
the rDNAs are expressed from telophase to the end of
G2 phase [26]. The AgNORs were displayed by a sil-
ver staining technique that selectively stains some acid
proteins (AgNOR proteins) associated with ribosomal
genes [27,28]. Silver-stained NORs are defined as
AgNORs and the argyrophilic NOR proteins as
AgNOR proteins [17,29]. Biochemical investigations
have revealed that two fundamental proteins, nucleolin
and nucleophosmin, are the major AgNOR proteins
[26,29]. Nucleolin is a phosphoprotein of 105 kDa
which plays an important role in the transcription of
rRNA molecules, and nucleophosmin (or B23 protein)
is a phosphoprotein of 38-39 kDa which is engaged in
the late steps of pre-ribosomal particle organization
[29]. The quantity of nucleolins and nucleophosmins
progressively increases from early G1 phase, reaches a
maximum value at the end of S phase and remains con-
stant up to the late G2 phase [26,29,30]. It has been
postulated that the quantity of AgNOR proteins as
detected by the silver staining is directly correlated
with transcriptional activity and proliferation rate of
the cell [17,29]. AgNORs can be visualised in routine
histological or cytological preparations as black or
dark brown dots in the interphase nucleus [27]. Evalu-
ation of the quantitative distribution of interphase
AgNORs has been applied in tumour pathology both
for diagnostic and prognostic purposes [17,29,31]. 
By using tissue microarray (TMA)-based immuno-
hisochemistry, we aimed at analyzing the expression
patterns of MCM2, MCM5 and MCM7 proteins, and
by using histochemical method of AgNOR proteins in
desmoid tumour cells. Additionally we examined
immunohistochemically the expression of Ki-67, 
a conventional proliferating antigen. 
Material and methods 
Formalin-fixed, paraffin-embedded archival tissues of 32 sporadic
aggressive fibromatosis (desmoid) were studied. Table 1 presents
the characteristics of the studied group. The tissues examined in
this study were collected from the same cases which were previ-
ously discussed by Stalinska et al. [32].
The analysed archival material was collected from the Polish
Departments of Tumor Pathology*. All the sections were inde-
pendently examined by two pathologists (AK, JS), using a confer-
ence microscope and they were histopathologically classified, as
recommended by The World Health Organization Classification of
Tumours (2002) [1] and Weiss, Goldblum [2]. The study was car-
ried out with full approval of the Local Ethics Committee. 
Tissue microarray (TMA). The paraffin-embedded tumour tissues
were used for constructing TMA blocks and studied for MCM2,
MCM5, MCM7 and Ki-67 expression by immunohistochemistry and
argyrophilic nucleolar organiser proteins (AgNORs) by histochemi-
cal method. Haematoxylin and eosin (H&E) stained sections were
made from paraffin blocks in order to mark the representative tumour
regions. The TMAs were constructed as previously described [33-
36]. From each specimen triplicate 2.0 mm tissue cores were punched
and arrayed on a recipient paraffin block. Soft tissue tumours are rel-
atively homogenous so the core samples should be representative of
the entire lesion [37]. The 5 m thick sections of tissue array blocks
were cut and placed on charged polylysine-coated slides (SuperFrost
®Plus, Menzel-Glaser, Brunschweig, Germany). The TMA com-
posed of tonsil samples were used as positive control. 
Immunohistochemical staining. The 5 μm thick TMA sections
were dried overnight at 60°C, then deparaffinized and rehydrated.
An antigen retrieval was performed by pretreatment in Target
Retrieval Solution Citrate (pH 6.0) (DAKO Cytomation, DK) in a
waterbath (95-99°C, 40 min.). The sections were subsequently
rinsed with 3% hydrogen peroxide for 10 min. at room temperature
and then they were incubated with primary mouse monoclonal
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Table 1. The examined group of desmoid tumour cases.
* two additional cases were included for the testing of MCM proteins
expression
antibodies for 1 hour at room temperature. The protein expression
was detected using LSAB®+SYSTEM-HR reagent (DAKO,
Cytomation, DK). 3,3'-diaminobenzidine (Liquid DAB + Chro-
mogen) (DAKO, Cytomation, DK) was used as chromogen to
yield brown reaction product. The sections were counterstained
with Mayers hematoxylin (DAKO, Cytomation, DK), dehydrated
and mounted. Negative controls were obtained by omission of the
primary antibody with substitution by non-specific immunoglobu-
lins. The mouse monoclonal antibodies were obtained in this study
from the Novocastra (Newcastle upon Tyne, UK) and diluted for
staining as follows: anti-MCM 2 (clone CRCT2.1), 1:50; anti-
MCM5 (clone CRCT5.1), 1:25; anti-MCM7 (clone DCS-141.1),
1:25, and Ki-67 (MIB-1) (DAKO, Cytometation, DK), 1: 50. The
TMA embedded tonsil sections were used as positive control for
MCM2, MCM5, and MCM7 (Fig. 1). The immunohistochemical
reaction for CD34 (clone QBEnd/10), (Novocastra, Newcastle
upon Tyne, UK), dilution 1:50, was performed for each case. 
Immunohistochemical analysis. A semiquantitative approach was
used for scoring the immunostaining [38]. The evaluation and scor-
ing of immunostaining was independently undertaken by two
pathologists (JS and JK); whenever necessary, a consensus was
reached using a double-headed microscope. The immunostaining
was also classified according to the location of the nucleus. The
MCM2, MCM5, MCM7 and Ki-67 were defined as positive cases
if  5% of all tumour cells stained positively [39]. The percentage of
positive cells was counted in each examined case in 10 high-power
fields (HPF) with 40× magnification of the objective lens. The
labeling index (LI) for MCM2, MCM5, MCM7, and K-67
immunoreactivity was made by scoring positive nuclei as a per-
centage of the total number of the counted nuclei. 
AgNORs staining. AgNORs staining was performed as reported
by Ploton et al. [27]. TMA sections, 5 μm thick, were oven dried
overnight at 60°C, then deparaffinized in xylene and following
this, hydrated through 3 decreasing concentrations of ethanol to
distilled water. The AgNOR staining solution was composed of one
volume of 2% solution of gelatin (Sigma, USA) in 1% aqueous
formic acid (Sigma, USA) and two volumes of 50% silver nitrate
(Sigma, USA). The staining reaction was performed for 16 minutes
in a dark chamber at 37°C. After washing, the sections were dehy-
drated through graded concentration of alcohol to xylene and
mounted in a synthetic medium. 
Morphometric analysis of AgNORs. Silver stained specimens
were examined using BX-41 OLYMPUS microscope equipped
with a PlanC × 100/1.25 oil lens. The images were digitized and
transferred directly into the computer with OLYMPUS C-5060
digital camera and QuickPHOTO PRO v.2.0 software with the
resolution 2592 × 1944 pixels. Semiautomated image processing
performed with Imagej v.1.34, included: conversion into 8 bit
image, background, normalization, highpass filtration, segmen-
tation, binary processing and final measurements. The number of
the analysed nuclei from each patient was 180-215. The nuclei
were chosen for the analysis systematically. The lymphocytes
from maturation region of lymphatic nodules of palatine tonsil
were the control group. The AgNOR analysis was in accordance
with the recommendations of the 'Committee on AgNOR Quan-
tification' within the European Society of Pathology [40]. The
following morphometric parameters were assessed: number of
cell nuclei, AgNOR dot number, and AgNOR area. The mean
number AgNORs per nucleus (N) and the mean AgNOR area per
silver-stained NOR particle (dot) (A) were calculated according
to:
Σ(AgNORs)              Σ(Area of AgNORs)
N =  –––––––––––– ,    A = –––––––––––––––––– . 
No. of cells                 No. of AgNORs   
The quotient of these parameters was regarded as an equivalent
of the AgNOR content of a given cell or tumor (C = N/A) [41].
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Fig. 1. Immunoreactivity of MCM7
in tonsil using tissue microarray.
Representative images of positive
expression are shown. Nuclei were
counterstained with Mayers hema-
toxilin. (A) MCM7 control (origi-
nal magnification ×25); (B) MCM7
control (original magnification
×40); (C) MCM7 control (original
magnification ×100); (D) MCM7
control (original magnification
×200).
Statistical analysis. The basic statistical analysis (arithmetic
mean, range, standard deviation) was performed. The comparisons
between the groups and the analysis of the dependences were per-
formed with chi2 test and Fisher's exact test. Pearson correlation
coefficient was applied to compare the expression of MCM and Ki-
67 proteins. The statistical analysis of the AgNOR parameters was
performed using regression analysis ANOVA. The value of p<0.05
was regarded as statistically significant.
Results 
The clinical data of the examined cases of desmoids
of extra-abdominal location are given in Table 2.
Among tumours of abdominal location 11 cases
occurred in abdominal wall and 7 in musculus rec-
tus. One of the tumours located intra-abdominally
was found in pelvis minor, the other in retroperi-
toneal space.
MCM2, MCM5, MCM7 and Ki-67 proteins
analysis 
Mean values of the percentage of MCM2, MCM5,
MCM7 and Ki-67-positive cells are presented in
Table 3. MCM7 nuclear expression was found in
20% (4/20) of desmoid cases (≥5% of tumour
nuclear staining), where mean percentage of positive
cells was 0.87 (SD±1.64) (range 0-5%) (Fig. 2). In
the remaining cases there was lack of MCM7 protein
expression or only single cells were noted with
nuclear staining for this protein. In 100% (32/32) of
the examined cases with desmoid tumour no nuclear
staining was detected for MCM2 and MCM5 pro-
teins. Ki-67 nuclear expression was observed in
19.0% (4/21) of the desmoid cases (≥5% of tumour
nuclear staining), where the mean percentage of pos-
itive cells was 0.81% (SD ±1.65) (range 0-5%). In
the remaining cases no nuclear expression was
detected for this protein neither the presence of sin-
gle Ki-67-positive cells was noted. 
CD34 antigen is commonly used to distinguish
aggressive fibromatosis from other mesenchymal
tumours, including GISTs (Gastrointestinal Stromal
Tumours). Desmoid cells do not show the expression
of this antigen. In the present study all 32 examined
cases were CD34-negative.
AgNORs analysis  
The distribution of standardised AgNOR parameters
is summarized in Table 4. The mean values of
AgNOR parameters for the examined group (n=30)
were the following: number: 4.34 (±0.11), area: 0.74
μm2 (±0.03), dot area: 0.18 μm2 (±0.01), and AgNOR
content: 23.73 (±1.85) (Fig. 3). No statistically sig-
nificant differences were found between the abdom-
inal (n=18) and extra-abdominal location (n=10) for
the examined AgNOR parameters (p>0.1). In the
control tissue (tonsil) the mean values of AgNOR
parameters were as follows: number: 1.75 (±0.73),
area: 0.56 μm2 (±0.06), dot area: 0.32 μm2 (±0.10),
and AgNOR content: 5.47 ( 0.87). The mean AgNOR
number per nucleus and mean AgNOR content in
desmoid tumours was statistically significantly high-
er as compared to the control (p<0.001).  
584 T. Ferenc et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 584 (581-588) 
Doi: 10.2478/v10042-010-0087-y
Table 2. The tumour location of extra-abdominal aggressive fibro-
matosis cases.
*p<0.001 compared to the control
Table 4. Standardized AgNOR parameters score in the examined
desmoid tumours.
Table 3. Immunohistochemical findings in the examined group of
desmoid tumours.
n – number of examined cases, N (%) – percentage of positive cases
Discussion 
In the available literature there is only one report relat-
ed to the studies on the expression of MCM5 protein in
desmoid tumour cells with the use of immunohisto-
chemistry [32]. However, MCM2 – MCM7 proteins
have been investigated with this method as prolifera-
tion markers in different types of neoplasms, includ-
ing: oesophageal cancer [11,13], myxofibrosarcoma
[23], breast cancer [14], gastrointestinal stromal
tumours (GISTs) [15]. Freeman et al. [10] examined
the expression of MCM2, MCM5 and MCM7 proteins
in tissue from various malignancies. As far as GISTs
are concerned, Huang et al. [15] qualified the values of
LI>10% of tumor nuclear staining as cases MCM2-
positive. In our study no positive cases were found for
MCM2 and MCM5 proteins. However, the expression
of MCM7 protein was observed in 4 (20%) (≥5% of
tumour nuclear staining) of the 20 examined desmoid
cases. Taking into account other neoplasms in respect
of MCM7, Ren et al. [24] analysed MCM7 expression
with immunohistochemical method in prostatic tissues
from both benign and aggressive lesions. In 61.4%
(62/101) of aggressive cases of prostate cancer the
level of MCM7 protein expression was ≥20% of posi-
tive cells. In the cases of benign lesions the percentage
of positive cells did not reach the value of 20% in any
of the analysed cases [24]. In the same study the
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Fig. 2. Immunoreactivity of MCM7
in desmoid tumour using tissue
microarray. Representative images
of positive expression are shown.
Nuclei were counterstained with
Mayers hematoxilin. (A) MCM7
desmoid (original magnification
×25); (B) MCM7 desmoid (original
magnification ×40); (C) MCM7
desmoid (original magnification
×100); MCM7 desmoid (original
magnification ×200).
Fig. 3. Representative images of a
tissue microarray for AgNOR stain-
ing in desmoid tumour (A) and ton-
sil (B; control) (the line on a large
image corresponds to 250 μm, the
line on a small image corresponds
to 25 μm).
authors investigated the number of copies of MCM7
gene in benign lesions and aggressive prostate cancers.
The amplification of MCM7 gene was not detected in
any of the examined benign lesions, however it was
observed in 45% (26/58) of aggressive prostatic can-
cers [24]. In the studies on endometrial carcinoma Li
et al. [7] noted the correlation between the level of
MCM7 protein expression and the grade of histologi-
cal malignancy of this carcinoma and the patients' age
at the time of the diagnosis. In patients younger than
45 years of age and in the cases of well-differentiated
endometrial carcinoma the level of MCM7 expression
was statistically significantly lower than in patients in
whom the carcinoma was poorly differentiated. Fur-
thermore, the level of MCM7 expression appeared to
be an independent prognostic factor of survival in
patients with endometrial carcinoma [7]. Xue et al.
[12] analysed the expression of MCM7 protein in var-
ious forms of gestational trophoblastic diseases
(GTD). In the cases of malignant choriocarcinoma the
level of MCM7 protein expression was statistically
significantly higher than in the cases of partial or com-
plete hydatidiform mole. On the other hand, in com-
plete hydatidiform mole MCM7 expression was statis-
tically significantly higher than in the tissue of normal
3-month placenta from spontaneous abortion [12].
MCM7 labeling index (LI) can also be used as a mark-
er of glioma grade since it appeared to be useful in the
discrimination between the samples with prevalent
oligodendroglial component and samples with a small-
cell component [42].
In this study we also examined the expression of
conventional proliferating antigen, Ki-67, which was
subjected to immunohistochemical analysis by other
researchers in desmoid tumour. Saito et al. [43] exam-
ined Ki-67 expression in 38 cases of aggressive fibro-
matosis without familial adenomatous polyposis
(FAP). In majority of cases the authors found no posi-
tive reaction to this antigen or they observed single
cells with nuclear staining for Ki-67. In this study, the
mean value of the labeling index (LI) calculated for
Ki-67 was 3.0 (0-28.0) [43]. Hoos et al. [44] did not
find nuclear staining for Ki-67 in 24 of the examined
cases of aggressive fibromatosis. Neither Kouho et al.
[45] detected any cells (or were few) with nuclear
staining of Ki-67 in 24 desmoid cases. 
Leithner et al. [39] examined 80 cases of desmoid
tumour. They classified the cases as positive at the
value of ≥5% of cells with clear nuclear staining for
Ki-67. Basing on this criterion 20 out of 80 (25%) of
the examined desmoid cases were positive for Ki-67.
Among these 20 positive cases, in 18 the expression of
Ki-67 was detected in 5-10% of cells and only in 2
cases it was >10% of cells with nuclear staining [39].
In the study of Gebert et al. [46] thirty six of 37 cases
showed MIB1 expression in ≤2% of the tumour cells.
In one case MIB1 expression was apparent in 5% of
the tumour cells. In our study in 4 of 21 (19%) cases
the expression of Ki-67 proteins was 5%.
A lot of studies have been already presented on
AgNORs in human neoplasms derived from various tis-
sues e.g. [16,28,31]. Khan et al. [47] examined 74
benign and 36 malignant soft tissue tumours. The mean
AgNOR count in malignant tissue was 4.96 (±1.33),
which was found to be higher as compared to both nor-
mal appearing soft tissues and benign soft tissues
tumours. The results were found to be statistically sig-
nificant [47]. So far, only few works have been available
concerning the analysis of AgNORs in aggressive fibro-
matosis tumours [48-49]. Egan et al. [48] examined 16
cases of fibrous proliferations of childhood. The fibrous
proliferations composed five cases of infantile digital
fibromatosis, seven infantile desmoids type fibromato-
sis and four of infantile myofibromatosis. These authors
demonstrated that the mean number of AgNORs in
fibromatoses is 3.7 (range 2.7-5.9) [48]. Schmidt et al.
[49] investigated AgNORs in 27 cases of infantile
desmoid-type fibromatosis. The AgNOR number per
cell varied considerably from case to case, with a medi-
an number of 4 (range 1.6-7.5). The authors noted
marked differences in AgNOR size – the size varied
between 0.14 and 0.45 μm2 (median 0.25 μm2) [49].
They found no correlation between AgNOR features
and the clinical course in 11 cases in which these stud-
ies were performed simultaneously [49].  
In our study, in 30 examined desmoid cases, the
mean AgNOR number per nucleus was 4.34 (±0.11), the
mean AgNOR area per nucleus was 0.74 (±0.03), and
the mean value of AgNOR dot area was: 0.18 (±0.01).
The high value of AgNOR content in the examined
group of desmoids caught the attention. Its mean value
was here 23.73 (±1.85) and it was statistically signifi-
cantly higher as compared to the control group where it
was 5.47 (±0.87) (p<0.001). The number of interphase
AgNORs is strictly related to rRNA transcriptional
activity [17,29]. Taking this into consideration, the
results obtained in the present study concerning the
number of AgNORs might be associated with the ele-
vated synthesis of collagen in desmoid cells.  
In this study, we have concluded that the low level
of MCM7, Ki-67 and lack of MCM2, MCM5 proteins
expression may explain commonly known low mitotic
activity of desmoid tumour cells. Morphology of
AgNOR dots (number, area) and their morphometric
parameters point to the elevated transcriptional activi-
ty of desmoid cells. 
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